IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by National Bank of Canada FI

National Bank of Canada FI increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 119.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 66,167 shares of the company’s stock after acquiring an additional 35,958 shares during the period. National Bank of Canada FI owned approximately 0.08% of IDEXX Laboratories worth $36,239,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Gotham Asset Management LLC lifted its holdings in IDEXX Laboratories by 79.9% in the 3rd quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after purchasing an additional 7,741 shares in the last quarter. NewEdge Wealth LLC boosted its stake in shares of IDEXX Laboratories by 30.4% during the 3rd quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after buying an additional 149 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after buying an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. raised its holdings in IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock valued at $9,112,000 after acquiring an additional 4,315 shares in the last quarter. Finally, Mitchell Capital Management Co. boosted its stake in IDEXX Laboratories by 1.3% during the 3rd quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after acquiring an additional 79 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $4.15 during trading hours on Monday, hitting $476.45. The stock had a trading volume of 116,027 shares, compared to its average volume of 440,730. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a market cap of $39.35 billion, a PE ratio of 46.52, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. The company has a 50-day moving average of $523.29 and a two-hundred day moving average of $513.58. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the firm earned $2.05 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.05 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on IDXX. JPMorgan Chase & Co. increased their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday. The Goldman Sachs Group increased their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $580.88.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,524 shares of company stock valued at $24,871,960. 2.18% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.